Gilead Sciences and Assembly Biosciences Update Collaboration on ABI-6250
Gilead Sciences maintains an option to license Assembly Biosciences' ABI-6250 for chronic HDV infection following the completion of a Phase 2 clinical study.
Stocks · News reference
Gilead Sciences Announces Third Quarter 2026 Financial Results
Gilead Sciences reported strong third-quarter 2026 financial results, exceeding analyst expectations for both revenue and earnings per share, and raised its full-year base business revenue guidance.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Breakfast News: Brace for an AI Optics Shake-up
Marvell is reportedly in advanced talks to acquire Lumentum to control AI optics supply, a critical bottleneck in AI infrastructure. Alphabet slumped 10% despite strong cloud growth due to massive capital expenditures and negative free cash flow. Several earnings reports showed mixed results: Fortinet fell 25% on weak guidance, ServiceNow dropped 19% due to AI deployment costs, while Microsoft, Sterling Infrastructure, and Chipotle posted gains. DoorDash may acquire Instacart to compete in grocery delivery dominated by Instacart's 68% market share.
Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
Kymera Therapeutics reported Q3 2026 financial results with positive Phase 1 data for KT-579 (IRF5 degrader) showing deep, sustained target degradation and favorable safety profile. The company is advancing KT-621 (STAT6 degrader) in Phase 2b trials for atopic dermatitis and asthma, with AD topline data expected by year-end 2026. Kymera maintains strong financial position with $1.6 billion in cash providing runway into 2029.